BIOMED REALTY TRUST, INC. [Member] |
Operating activities: |
Net income |
91.45M |
Adjustments to reconcile net income to net cash provided by operating activities: |
Depreciation and amortization |
Allowance for doubtful accounts |
1.87M |
Non-cash revenue adjustments |
1.27M |
Other non-cash adjustments |
10M |
Compensation expense related to restricted common stock and LTIP units / share-based payments |
14.81M |
Distributions representing a return on capital from unconsolidated partnerships |
1.89M |
Changes in operating assets and liabilities: |
Restricted cash |
Accounts receivable |
-4.72M |
Accrued straight-line rents |
Deferred leasing costs |
-30.61M |
Other assets |
-9.14M |
Security deposits |
Accounts payable, accrued expenses and other liabilities |
12.93M |
Net cash provided by operating activities |
206.54M |
Investing activities: |
Purchases of interests in and additions to investments in real estate and related intangible assets |
-210.51M |
Purchases of equity securities |
-33.78M |
Proceeds from the sale of equity securities |
90.38M |
Funds held in escrow for acquisitions |
Net cash used in investing activities |
-403.56M |
Financing activities: |
Proceeds from common stock offering |
Payment of common stock offering costs |
Payment of deferred loan costs |
-78K |
Unsecured line of credit proceeds |
407M |
Unsecured line of credit payments |
-28M |
Principal payments on mortgage notes payable |
-28.56M |
Secured term loan repayments |
Repurchases of exchangeable senior notes due 2026 |
Proceeds from exchangeable senior notes due 2030 |
Proceeds from unsecured senior notes |
0 |
Deferred settlement payments on interest rate swaps, net |
Distributions to operating partnership unit and LTIP unit holders |
-4.21M |
Dividends paid to common stockholders/unitholders |
-161.4M |
Dividends paid to preferred stockholders/unitholders |
Net cash provided by financing activities |
199.35M |
Net (decrease)/increase in cash and cash equivalents |
2.02M |
Cash and cash equivalents at beginning of period |
46.66M |
Cash and cash equivalents at end of period |
48.68M |
Supplemental disclosure of cash flow information: |
Cash paid during the period for interest (net of amounts capitalized of $3,311 and $2,946, respectively) |
45.56M |
Supplemental disclosure of non-cash investing and financing activities: |
Accrual for preferred stock/unit dividends/distributions declared |
Accrual for common stock/unit dividends/distributions declared |
54.32M |
Accrual for distributions declared for operating partnership unit and LTIP unit holders |
1.4M |
Accrued additions to real estate and related intangible assets |
117.03M |
BIOMED REALTY, L.P. [Member] |
Operating activities: |
Net income |
91.45M |
Adjustments to reconcile net income to net cash provided by operating activities: |
Depreciation and amortization |
Allowance for doubtful accounts |
1.87M |
Non-cash revenue adjustments |
1.27M |
Other non-cash adjustments |
10M |
Compensation expense related to restricted common stock and LTIP units / share-based payments |
14.81M |
Distributions representing a return on capital from unconsolidated partnerships |
1.89M |
Changes in operating assets and liabilities: |
Restricted cash |
Accounts receivable |
-4.72M |
Accrued straight-line rents |
Deferred leasing costs |
-30.61M |
Other assets |
-9.14M |
Security deposits |
Accounts payable, accrued expenses and other liabilities |
12.93M |
Net cash provided by operating activities |
206.54M |
Investing activities: |
Purchases of interests in and additions to investments in real estate and related intangible assets |
-210.51M |
Purchases of equity securities |
-33.78M |
Proceeds from the sale of equity securities |
90.38M |
Funds held in escrow for acquisitions |
Net cash used in investing activities |
-403.56M |
Financing activities: |
Proceeds from issuance of OP units |
Payment of deferred loan costs |
-78K |
Unsecured line of credit proceeds |
407M |
Unsecured line of credit payments |
-28M |
Principal payments on mortgage notes payable |
-28.56M |
Secured term loan repayments |
Repurchases of exchangeable senior notes due 2026 |
Proceeds from exchangeable senior notes due 2030 |
Proceeds from unsecured senior notes |
0 |
Deferred settlement payments on interest rate swaps, net |
Dividends paid to common stockholders/unitholders |
-157.19M |
Dividends paid to preferred stockholders/unitholders |
Net cash provided by financing activities |
199.35M |
Net (decrease)/increase in cash and cash equivalents |
2.02M |
Cash and cash equivalents at beginning of period |
46.66M |
Cash and cash equivalents at end of period |
48.68M |
Supplemental disclosure of cash flow information: |
Cash paid during the period for interest (net of amounts capitalized of $3,311 and $2,946, respectively) |
45.56M |
Supplemental disclosure of non-cash investing and financing activities: |
Accrual for preferred stock/unit dividends/distributions declared |
Accrual for common stock/unit dividends/distributions declared |
52.92M |
Accrued additions to real estate and related intangible assets |
117.03M |